Depestel Daryl D, Aronoff David M
Medical Affairs, Cubist Pharmaceuticals Inc, Lexington, MA, USA.
J Pharm Pract. 2013 Oct;26(5):464-75. doi: 10.1177/0897190013499521.
There has been dramatic change in the epidemiology of Clostridium difficile infection (CDI) since the turn of the 21st century noted by a marked increase in incidence and severity, occurring at a disproportionately higher frequency in older patients. Historically considered a nosocomial infection associated with antibiotic exposure, CDI has now also emerged in the community in populations previously considered low risk. Emerging risk factors and disease recurrence represent continued challenges in the management of CDI. The increased incidence and severity associated with CDI has coincided with the emergence and rapid spread of a previously rare strain, ribotype 027. Recent data from the United States and Europe suggest that the incidence of CDI may have reached a crescendo in the recent years and is perhaps beginning to plateau. The acute care direct costs of CDI were estimated to be US$4.8 billion in 2008. However, nearly all the published studies have focused on CDI diagnosed and treated in the acute care hospital setting and fail to measure the burden outside the hospital, including recently discharged patients, outpatients, and those in long-term care facilities. Enhanced surveillance methods are needed to monitor the incidence, to identify populations at risk, and to characterize the molecular epidemiology of strains causing CDI.
自21世纪之交以来,艰难梭菌感染(CDI)的流行病学发生了显著变化,其发病率和严重程度显著增加,在老年患者中出现的频率尤其高。CDI在历史上被认为是一种与抗生素暴露相关的医院感染,现在也出现在以前被认为低风险的社区人群中。新出现的风险因素和疾病复发仍是CDI管理中的持续挑战。与CDI相关的发病率和严重程度增加与一种以前罕见的菌株——核糖体分型027的出现和迅速传播同时发生。来自美国和欧洲的最新数据表明,近年来CDI的发病率可能已达到顶峰,或许开始趋于平稳。2008年,CDI的急性护理直接成本估计为48亿美元。然而,几乎所有已发表的研究都集中在急性护理医院环境中诊断和治疗的CDI,未能衡量医院外的负担,包括近期出院的患者、门诊患者以及长期护理机构中的患者。需要加强监测方法来监测发病率、识别高危人群,并描述引起CDI的菌株的分子流行病学特征。